News

The study will examine the effectiveness of PLX-R18 as a treatment for Acute Radiation Syndrome (ARS) prior to, and within the first 24 hours of exposure to radiation.

The financing was co-led by new investor Wellington Management Company LLP and by a large US-based, healthcare-focused fund, participating as an existing Atreca investor. Additional participation included new

The FDA assessed and approved Besponsa under the breakthrough therapy designation and priority review programs. Besponsa is a targeted therapy, which is believed to work by binding to B-cell

Based in Baltimore, Maryland, Insilico Medicine is an American biotechnology startup that uses AI research for drug discovery, aging research and biomarker development. The collaboration to discover novel biological

This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation. Evotec paid a total consideration of

In November 2016, the FDA granted ADCETRIS Breakthrough Therapy Designation (BTD) for the treatment of patients with CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma who

CA4P is Mateon’s investigational drug, as well as potent and tubulin-binding vascular disrupting agent (VDA). Focus study is assessing CA4P in combination with bevacizumab and physician's choice chemotherapy

Working with well-established and recognized brands in Russia including Lactacyd, Aflubin and Paranit, the firm focuses on a targeted portfolio of over-the-counter drugs in categories such as women’s

The Principal Investigator is Dr. James D. Blanchard, Principal Scientist, Preclinical Development at Aradigm. Professor Luiz Bermudez at Oregon State University, Corvallis, will lead the laboratory research as